Approval · Notice of Compliance 25097 · 2021
RIVASTIGMINE PATCH 10: Notice of Compliance 25097
Issued January 28, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25097
- Date
- January 28, 2021
- Company
- Strides Pharma Canada IncVaughan, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Labelling Only
- Reason
- Product name change. updating the product monograph and package insert
- Canadian reference product
- EXELON PATCH (Novartis Pharmaceuticals Canada Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RIVASTIGMINE PATCH 10 | 02479559 | Dormant |
| RIVASTIGMINE PATCH 15 | 02479567 | Dormant |
| RIVASTIGMINE PATCH 5 | 02479540 | Dormant |
Medicinal ingredients
- RIVASTIGMINE 9.5 MG per DAY
- RIVASTIGMINE 13.3 MG per DAY
- RIVASTIGMINE 4.6 MG per DAY